UBS Group’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-335,678
| Closed | -$15.9M | – | 10453 |
|
|
2025
Q3 | $15.9M | Sell |
335,678
-1,693,209
| -83% | -$82M | ﹤0.01% | 2817 |
|
|
2025
Q2 | $108M | Sell |
2,028,887
-127,519
| -6% | -$5.79M | 0.02% | 912 |
|
|
2025
Q1 | $87.3M | Buy |
2,156,406
+1,784,562
| +480% | +$75.6M | 0.02% | 1013 |
|
|
2024
Q4 | $10.3M | Buy |
371,844
+277,043
| +292% | +$8.39M | ﹤0.01% | 3003 |
|
|
2024
Q3 | $2.72M | Buy |
94,801
+23,690
| +33% | +$618K | ﹤0.01% | 3688 |
|
|
2024
Q2 | $1.67M | Sell |
71,111
-136,890
| -66% | -$2.93M | ﹤0.01% | 3955 |
|
|
2024
Q1 | $5.25M | Sell |
208,001
-58,385
| -22% | -$1.4M | ﹤0.01% | 2919 |
|
|
2023
Q4 | $6.22M | Buy |
266,386
+207,983
| +356% | +$4.1M | ﹤0.01% | 2539 |
|
|
2023
Q3 | $2.95M | Buy |
58,403
+31,968
| +121% | +$1.49M | ﹤0.01% | 3075 |
|
|
2023
Q2 | $1.23M | Sell |
26,435
-66,997
| -72% | -$3.07M | ﹤0.01% | 4034 |
|
|
2023
Q1 | $3.57M | Sell |
93,432
-45,548
| -33% | -$2.03M | ﹤0.01% | 2842 |
|
|
2022
Q4 | $7.62M | Buy |
138,980
+135,262
| +3,638% | +$5.8M | ﹤0.01% | 2119 |
|
|
2022
Q3 | $127K | Buy |
3,718
+218
| +6% | +$3.34K | ﹤0.01% | 5496 |
|
|
2022
Q2 | $33K | Sell |
3,500
-63,065
| -95% | -$658K | ﹤0.01% | 6292 |
|
|
2022
Q1 | $945K | Buy |
66,565
+9,725
| +17% | +$170K | ﹤0.01% | 4155 |
|
|
2021
Q4 | $1.2M | Buy |
56,840
+13,588
| +31% | +$301K | ﹤0.01% | 4222 |
|
|
2021
Q3 | $967K | Buy |
43,252
+32,951
| +320% | +$746K | ﹤0.01% | 4223 |
|
|
2021
Q2 | $255K | Sell |
10,301
-18,308
| -64% | -$514K | ﹤0.01% | 5181 |
|
|
2021
Q1 | $830K | Buy |
28,609
+22,455
| +365% | +$680K | ﹤0.01% | 4437 |
|
|
2020
Q4 | $159K | Buy |
6,154
+4,463
| +264% | +$124K | ﹤0.01% | 5379 |
|
|
2020
Q3 | $52K | Buy |
1,691
+239
| +16% | +$8.35K | ﹤0.01% | 5616 |
|
|
2020
Q2 | $36K | Buy |
1,452
+441
| +44% | +$10.1K | ﹤0.01% | 6132 |
|
|
2020
Q1 | $21K | Sell |
1,011
-2,250
| -69% | -$48.3K | ﹤0.01% | 6454 |
|
|
2019
Q4 | $72K | Sell |
3,261
-2,847
| -47% | -$58.9K | ﹤0.01% | 6161 |
|
|
2019
Q3 | $139K | Buy |
6,108
+4,990
| +446% | +$116K | ﹤0.01% | 5538 |
|
|
2019
Q2 | $21K | Buy |
+1,118
| New | +$21.2K | ﹤0.01% | 6576 |
|
Other funds holding AKRO
UBS Group's AKRO Position: Q4 2025 in Review
UBS Group sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 335,678 shares — an estimated $15.9M sold.
UBS Group first reported a position in AKRO in Q2 2019 and held it in 26 quarters. The position peaked at $108M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- UBS Group reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- UBS Group sold 335,678 Akero Therapeutics shares in Q4 2025, an estimated $15.9M.
- UBS Group first reported a position in Akero Therapeutics in Q2 2019 and held it in 26 quarters.
- UBS Group's Akero Therapeutics position peaked at $108M in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.